Ocular Quinine Toxicity and Hyperbaric Oxygen

By Rubicon Foundation editorial team

5 min read · 1 November 2026

Ocular quinine toxicity treated with hyperbaric oxygen is a 1997 journal article by Wolff RS and colleagues in Undersea & Hyperbaric Medicine 24(2). Its subject is the intersection of quinine-related eye injury and hyperbaric oxygen therapy, a clinical question relevant to understanding oxygen delivery, retinal function and the limits of treatment evidence.

What does quinine toxicity mean for the eye?

Quinine is a drug that can cause toxic effects in the visual system. Ocular toxicity may involve the retina, the light-sensitive tissue lining the back of the eye, and can impair how visual signals are detected and transmitted. The exact pattern and severity depend on the clinical circumstances.

The retina has high metabolic demands and relies on a continuous supply of oxygen. Injury can disrupt its function even when the eye looks structurally intact. For clinicians, distinguishing toxic effects from other causes of visual loss is central to evaluating the problem and considering treatment.

Why consider hyperbaric oxygen?

Hyperbaric oxygen therapy exposes a patient to oxygen at a pressure above that of the surrounding atmosphere. Raising the pressure increases the amount of oxygen dissolved in blood plasma, in addition to the oxygen carried by haemoglobin. This can alter oxygen availability to tissues, though it does not by itself establish that damaged tissue will recover.

For an eye condition, the rationale turns on whether oxygen delivery is a relevant constraint and whether additional dissolved oxygen can reach affected tissue in a useful way. The potential benefit must be weighed against the cause and timing of injury, the state of the circulation, and the risks and practical demands of chamber treatment.

What questions does this kind of work address?

A clinical report on ocular toxicity and hyperbaric oxygen sits within a broader effort to understand when pressure-based oxygen treatment may be useful beyond familiar diving emergencies. The subject raises questions about mechanism, treatment timing, visual function and how clinicians judge change after an intervention.

Mechanism: Is impaired oxygen supply part of the tissue injury, or is toxicity acting through another process?
Timing: Does the interval between exposure, symptoms and treatment affect the clinical question?
Assessment: Which measures of vision and retinal function are relevant to tracking a case?
Safety: How should the potential benefits of chamber exposure be balanced against its risks?

These considerations matter because biological plausibility and clinical effectiveness are different questions. A treatment may have a coherent physiological rationale without that rationale alone determining whether it improves a patient’s outcome.

How does this connect to diving medicine?

Diving medicine routinely considers how pressure and gas affect the body, including the consequences of altered oxygen availability. Hyperbaric treatment is also used in selected conditions unrelated to diving. A paper concerning an eye toxicity therefore belongs to the wider hyperbaric literature, while remaining distinct from research on decompression illness or gas embolism.

For divers, the relevance is chiefly clinical and conceptual: visual symptoms can affect safety, and treatment decisions involving chamber exposure require a diagnosis rather than an assumption that oxygen is beneficial. A diver with new visual disturbance should stop diving and seek prompt medical assessment; a diving-medicine physician can help evaluate fitness to return.

What should readers take from the subject?

The article’s title identifies a focused clinical problem: quinine-associated ocular toxicity considered in relation to hyperbaric oxygen. It brings together pharmacological injury, retinal physiology and a treatment whose effects depend on both tissue biology and clinical context.

For clinicians and researchers, the enduring questions are how the injury affects visual function, whether oxygen delivery is modifiable, and what evidence is needed to judge treatment. Any decision about hyperbaric therapy belongs with appropriately qualified clinicians, including an ophthalmic and hyperbaric assessment where relevant.

Frequently asked questions

What is ocular quinine toxicity?

It is harmful drug-related effect on the visual system associated with quinine. The specific eye structures affected and the severity vary by clinical case.

Why might hyperbaric oxygen be considered?

Hyperbaric oxygen increases oxygen dissolved in plasma by exposing the patient to oxygen under increased pressure. Whether that is useful for a particular eye injury depends on the underlying mechanism and clinical evidence.

Does this topic apply directly to diving emergencies?

It concerns hyperbaric medicine, but ocular quinine toxicity is distinct from decompression illness. New visual symptoms after diving require prompt medical evaluation rather than self-diagnosis or self-treatment.

Citation details

Title: Ocular quinine toxicity treated with hyperbaric oxygen
Authors: Wolff RS; Wirtschafter D; Adkinson C
Year: 1997
Published in: Undersea & Hyperbaric Medicine 24(2)
Identifiers: PMID 9171472
Record type: Journal article
Repository record: Rubicon Research Repository, handle 123456789/2278

This page is an original summary written by the Rubicon editors from the publication’s bibliographic record. It does not reproduce the paper, its abstract or its data; consult the publication itself for its methods and findings.